{"entity":{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","aka":[],"tldr":"A phase 1/2 trial of ENV-501 in melanoma and non-small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.","summary":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT06956690 by Hummingbird Bioscience, with 180 participants planned, started 2025-12-17 and due to reach its primary completion in 2027-07. Interventions recorded: ENV-501. Conditions listed: Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06956690","url":"https://clinicaltrials.gov/study/NCT06956690"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["env-501"],"companies":["hummingbird-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06956690","phase":"1/2","setting":"A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors","sponsor":"Hummingbird Bioscience","participation":[{"nct":"NCT06956690","source":"https://clinicaltrials.gov/study/NCT06956690","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"b3f018d4c2705776ba9097245ac241c3628e92ef9706ec3a1016677e3c4fcce8","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-02","leadSponsor":"Hummingbird Bioscience","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":7,"recruitingSiteCount":5,"countries":["Australia","United States"]}],"started":"2025-12-17","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06956690/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/"}],"company":[{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","route":"/companies/hummingbird-bioscience/"}]}}